drugset / Trial / NCT02732015
Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy
RandomizedParallel-groupOpen-labelSupportive care
Summary
This randomized phase II trial studies how well rolapitant hydrochloride works in preventing nausea/vomiting in patients with sarcoma receiving chemotherapy. Antiemetic drugs, such as rolapitant hydrochloride, may help control or prevent nausea and vomiting in patients treated with chemotherapy.
Timeline
- Start
- 2016-10-12
- Primary completion
- 2020-07-10
- Completion
- 2020-07-10
Outcome
Outcome not reported
Stopped: “Terminated per PI's request”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rolapitant | Small molecule | — | Oral |
| Comparator | fosaprepitant dimeglumine | Unknown | — | Intravenous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Intravenous |
| Background | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | Ifosfamide | Small molecule | — | Intravenous |
| Background | Ondansetron | Other / unclassified | — | Intravenous |
| Background | Vincristine | Small molecule | — | Intravenous |